Celldex Therapeutics, Inc. (NASDAQ:CLDX)

CAPS Rating: 3 out of 5

A biopharmaceutical company engaged in the discovery, development and commercialization of products that harness the human immune response to prevent and treat disease.

Results 1 - 20 of 43 : 1 2 3 Next »

Recs

0
Member Avatar pchop12316 (76.91) Submitted: 6/23/2015 3:34:08 PM : Outperform Start Price: $26.26 CLDX Score: -5.04

solid citizen that is likely to rebound

Recs

0
Member Avatar marsuculix (64.41) Submitted: 6/12/2015 8:08:37 AM : Outperform Start Price: $25.31 CLDX Score: -2.21

CDX-110 has a BTD and phase3 data in GBM patients will be convincing!

Recs

1
Member Avatar zzlangerhans (99.83) Submitted: 6/2/2015 3:12:16 PM : Outperform Start Price: $28.19 CLDX Score: -11.73

Celldex is looking like a pretty safe bet not to go back into the teens after netting 189M from a public offering at 24 in February and presenting solid if not jaw-dropping data from ReACT at ASCO. There's been some muttering about submitting Rintega for accelerated approval in the recurrent GBM population which could lead to some disappointment and backsliding in share price if that fails to materialize. An interim analysis of the ACT IV phase III trial of Rintega as first line therapy after surgical resection of EGFRvIII+ GBM is also expected in the near future. It's hard to tell whether the market will react negatively to a trial continuation after the interim analysis. Management has not been raising expectations. However, if there is a decline that might be an opportune time to enter the stock. Meanwhile, the METRIC phase III trial of glembotumumab in triple negative breast cancer and combination trials of varlilum and PD-1 inhibitors in solid tumors continue to enroll.

Recs

0
Member Avatar Med51 (65.65) Submitted: 5/21/2015 11:41:16 PM : Outperform Start Price: $27.19 CLDX Score: -7.76

If even one of their drugs makes it to market they will make a very healthy profit and revenue stream.

Recs

0
Member Avatar clangmead (29.59) Submitted: 5/15/2015 6:39:34 AM : Outperform Start Price: $25.73 CLDX Score: -2.95

good candidates

Recs

0
Member Avatar derbydog85 (32.80) Submitted: 3/2/2015 11:25:33 AM : Outperform Start Price: $27.02 CLDX Score: -7.82

This is a great company that looks to cure cancers that there is currently no or few options. A brain cancer drug has been approved for phase 3 trials by the FDA. These guys are great for humanity.

Recs

0
Member Avatar ptanabe (75.99) Submitted: 2/26/2015 6:29:50 PM : Outperform Start Price: $21.93 CLDX Score: +9.66

BTD

Recs

0
Member Avatar sullyz0r (84.89) Submitted: 11/25/2014 10:22:45 PM : Outperform Start Price: $20.38 CLDX Score: +19.47

A bit late on this one, but better late than later.

Recs

0
Member Avatar DLester78 (73.65) Submitted: 9/29/2014 6:00:35 PM : Outperform Start Price: $13.70 CLDX Score: +72.87

oversold... tons of risk, could be no reward.

Recs

1
Member Avatar asilverp (28.26) Submitted: 8/28/2014 12:25:20 PM : Underperform Start Price: $15.94 CLDX Score: -49.20

p/s of over 500 and losing money.

Recs

0
Member Avatar stockgripes (99.43) Submitted: 8/21/2014 4:05:09 PM : Outperform Start Price: $14.30 CLDX Score: +66.28

time to switch the thumb again

Recs

0
Member Avatar wimmreuter (31.61) Submitted: 9/26/2013 2:22:01 PM : Outperform Start Price: $35.18 CLDX Score: -53.24

Coming down from the high 80s and now slowly being successful with their medication is the a long way to go but rewards are coming.

Recs

0
Member Avatar Teknowizz (94.09) Submitted: 9/25/2013 3:06:12 AM : Outperform Start Price: $34.48 CLDX Score: -51.59

OK let's see whether she will run some more.
Really stopped this too early in order to bank the +300 run :)

Recs

2
Member Avatar bignr15 (< 20) Submitted: 7/7/2013 3:36:34 PM : Outperform Start Price: $21.40 CLDX Score: -12.73

Huge Growth Potential, could hit $60 in 2 years. Will be lots of ups and downs, so have long term view on this one.

Recs

0
Member Avatar FoolsLint (< 20) Submitted: 7/6/2013 4:59:20 PM : Outperform Start Price: $21.40 CLDX Score: -12.73

The demand for cancer cure. The success this company is having . The effect that this company is having on breast cancer is a very good start.

Recs

0
Member Avatar TheStockDoctor (< 20) Submitted: 6/11/2013 7:15:03 AM : Outperform Start Price: $15.14 CLDX Score: +33.88

Pipeline is strong and competition is minimal.

Recs

1
Member Avatar MyManDon1 (< 20) Submitted: 7/20/2012 11:38:21 AM : Outperform Start Price: $5.38 CLDX Score: +301.06

1) market cap of only $300MM
2) has cash on hand to get through PIII with leading drugs
3) owns most important drugs outright keeping significant potential for homegrown profits inhouse and/or leaving room for partnership and/or full buyout
4) multiple drugs in pII providing cushion agains setback (i.e. limited downside risk)
5) management/science presentations exhibit sound planning and strategy that is needed to succeed
6) partnership activity is picking up due to patent cliffs at many big pharmas

Recs

1
Member Avatar rangarajud (50.39) Submitted: 5/16/2012 5:31:51 PM : Outperform Start Price: $4.47 CLDX Score: +388.71

great stock with huge pipeline and promising drug status on May 23rd 2012 will send this stock north of 7$.

Recs

1
Member Avatar stainsolution (86.71) Submitted: 4/24/2012 3:24:49 PM : Outperform Start Price: $3.96 CLDX Score: +462.97

ASCO run---might be a little early here.

Recs

1
Member Avatar RBuskey106 (68.76) Submitted: 3/21/2012 8:22:30 PM : Outperform Start Price: $4.77 CLDX Score: +362.46

ASCO pick

Results 1 - 20 of 43 : 1 2 3 Next »

Featured Broker Partners


Advertisement